Sun Pharma Eyes $10 Billion Organon Acquisition to Boost US Market Presence

• Sun Pharmaceutical Industries Ltd is considering acquiring US-based Organon, a women's healthcare and biosimilars company.
• The potential $10 billion deal, including debt, would be Sun Pharma's largest cross-border acquisition and a significant move for founder Dilip Shanghvi.
• This acquisition aims to substantially strengthen Sun Pharma's footprint in the US pharmaceutical market.
• Organon, spun off from MSD in 2021 with significant debt, has been exploring asset divestments.
• Organon's stock surged recently amid sale expectations, following a previous drop due to alleged sales irregularities and CEO change.

Why It Matters: Sun Pharma is exploring a major $10 billion acquisition of Organon to expand its US market presence.